New Treatment Shows Long-Term Success for Muscular Dystrophy
新型療法在肌肉萎縮症治療上展現長期成效
更新於: 2026年6月27日 上午03:15
Recent breakthroughs in treating Duchenne Muscular Dystrophy (DMD) are transforming the medical landscape from basic symptom management to precision molecular medicine.
杜氏肌肉營養不良症(DMD)治療領域的最新突破，正將醫療前景從基礎的症狀管理轉向精準分子醫學。
DMD, characterized by a lack of dystrophin, typically results in muscle degeneration and chronic inflammation.
DMD以缺乏抗肌萎縮蛋白為特徵，通常會導致肌肉退化和慢性發炎。
However, recent FDA approvals, such as the HDAC inhibitor givinostat, now offer new hope by slowing the decline of mobility functions in patients aged six and older.
然而，近期的美國食品藥物管理局(FDA)批准，例如組織蛋白去乙醯酶抑制劑givinostat，現在為六歲及以上患者提供了延緩行動功能衰退的新希望。
Beyond drug therapy, researchers are pioneering gene delivery platforms that overcome traditional limitations.
除了藥物療法，研究人員正在開創克服傳統限制的基因傳遞平台。
A notable innovation as of June 2026 involves using extracellular vesicles to deliver the full-length DMD gene.
截至2026年6月，一項值得注意的創新涉及利用細胞外囊泡來傳遞全長DMD基因。
Unlike viral-based methods, which can trigger immune reactions, these engineered particles restore dystrophin production safely and effectively in preclinical models.
與可能引發免疫反應的病毒基底方法不同，這些工程化粒子能在臨床前模型中安全且有效地恢復抗肌萎縮蛋白的產生。
While therapies like Elevidys and exon-skipping drugs provide essential benefits, the field is increasingly focused on long-term durability and protecting vital organs.
儘管像Elevidys和外顯子跳躍藥物這類療法提供了重要益處，但該領域越來越關注長期耐用性及保護重要器官。
As these strategies evolve, the goal is clear: to extend lives, enhance muscle endurance, and provide lasting functional stability through innovative, targeted science.
隨著這些策略的演進，目標十分明確：透過創新且具標靶性的科學，延長生命、增強肌肉耐力並提供持久的功能穩定性。
